- Home
- MAIA vs BEAT Comparison
MAIA vs BEAT Comparison
Compare MAIA & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- BEAT
- Stock Information
- Founded
- MAIA 2018
- BEAT 2015
- Country
- MAIA United States
- BEAT United States
- Employees
- MAIA N/A
- BEAT 21
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- MAIA Health Care
- BEAT Technology
- Exchange
- MAIA Nasdaq
- BEAT Nasdaq
- Market Cap
- MAIA 46.7M
- BEAT 59.0M
- IPO Year
- MAIA 2022
- BEAT 2021
- Fundamental
- Price
- MAIA $2.03
- BEAT $1.78
- Analyst Decision
- MAIA
- BEAT Buy
- Analyst Count
- MAIA 0
- BEAT 1
- Target Price
- MAIA N/A
- BEAT $8.00
- AVG Volume (30 Days)
- MAIA 319.8K
- BEAT 55.5K
- Earning Date
- MAIA 05-20-2025
- BEAT 05-13-2025
- Dividend Yield
- MAIA N/A
- BEAT N/A
- EPS Growth
- MAIA N/A
- BEAT N/A
- EPS
- MAIA N/A
- BEAT N/A
- Revenue
- MAIA N/A
- BEAT N/A
- Revenue This Year
- MAIA N/A
- BEAT N/A
- Revenue Next Year
- MAIA N/A
- BEAT N/A
- P/E Ratio
- MAIA N/A
- BEAT N/A
- Revenue Growth
- MAIA N/A
- BEAT N/A
- 52 Week Low
- MAIA $1.40
- BEAT $1.45
- 52 Week High
- MAIA $5.99
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- MAIA 53.91
- BEAT 52.25
- Support Level
- MAIA $1.80
- BEAT $1.78
- Resistance Level
- MAIA $2.18
- BEAT $1.91
- Average True Range (ATR)
- MAIA 0.30
- BEAT 0.14
- MACD
- MAIA -0.01
- BEAT 0.02
- Stochastic Oscillator
- MAIA 30.29
- BEAT 49.39
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.